Trial Profile

A Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Trial to Evaluate the Equivalence in Efficacy and Safety of HD203 and Enbrel in Combination With Methotrexate in Patients With Rheumatoid Arthritis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Oct 2021 Results of meta-analysis of 3 randomized controlled trials (NCT01270997; NCT01895309 & NCT02357069) assessing efficacy and safety of etanercept biosimilars vs. etanercept originators in patients with active rheumatoid arthritis despite treatment with methotrexate, published in the International Journal of Clinical Pharmacology and Therapeutics.
23 Feb 2016 Results published in the Annals of the Rheumatic Diseases
14 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com